ClinicalTrials.gg
RecruitingNCT06031623REBOAUpdated Jan 28, 2025

REBOA in Nontraumatic OHCA

An interventional study of REBOA in Cardiopulmonary Arrest, sponsored by Seoul National University Hospital. Recruiting at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Seoul National University Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Oct 2025, 1 year 1 month ago, but the record still lists the study as recruiting.
  • Started Oct 2023; still recruiting 3 years 1 month later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
234
Allocation
Randomized
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 12 studies in Heart Arrest by Seoul National University Hospital — 4 open to participants now, 5 under way, none of them phase 3. Heart Arrest · Seoul National University Hospital.

Started
2023
the only one that year
No phase
8 of 12
3 open now
Registered
8th of 12
by date

Among the 12 studies in Heart Arrest by Seoul National University Hospital, this one is the only one that started in 2023, is one of 8 with no phase, and was the 8th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

4 of the 12 studies in Heart Arrest by Seoul National University Hospital are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Where they have run

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 12 studies in Heart Arrest by Seoul National University Hospital, or all of them as a file.
02

Study summary

The investigators propose a multicenter randomized controlled trial in South Korea and Taiwan to observe the clinical effects of REBOA on nontraumatic out-of-hospital-cardiac-arrest (OHCA) patients. While REBOA has been traditionally used in trauma for hemorrhage control, it has also shown promising results in nontraumatic cardiac arrests by rerouting circulation to increase perfusion in the coronary and brain.

Read the detailed description

Nontraumatic OHCA patients arriving at the 2 participating hospitals between the ages of 20 to 80 will be eligible. If the patient meets the enrollment criteria, he/she will be randomized into the control group (treatment with conventional ACLS according to the 2020 AHA guideline) or the REBOA group (ACLS according to the 2020 AHA guideline with REBOA application). A sheath catheter is inserted with ultrasound guidance to gain access to the common femoral artery in both groups. This is followed by insertion of the REBOA catheter, if the patient is allocated into the intervention group. The aortic balloon is inflated. If ROSC is achieved, the balloon is deflated slowly. Patients who achieve ROSC will receive post cardiac arrest management according to the 2020 AHA guideline.

03

Conditions studied

  • Cardiopulmonary Arrest

Browse trials for

Keywords

  • Advanced cardiopulmonary resuscitation (ACLS)
  • Cardiopulmonary resuscitation (CPR)
  • Resuscitative endovascular balloon occlusion of the aorta (REBOA)
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult nontraumatic OHCA
  • Witnessed arrest
  • Arrival at ER from 9AM to 5PM (in South Korea) and 8AM to 8PM (in Taiwan)

Exclusion criteria

Exclusion Criteria:

  1. age below 20 years old or over 80 years old,
  2. traumatic cardiac arrest,
  3. those with unwitnessed cardiac arrest,
  4. pregnant patients,
  5. patients who have already achieved ROSC upon arrival at the emergency department
  6. pre-cardiac arrest cerebral performance category of 3-4
  7. those showing evidence of cardiac arrest due to bleeding (such as gastrointestinal bleeding)
  8. those suspected of having aortic disease, such as dissection, intramural hematoma, or aneurysm, by bedside ultrasound performed immediately after ED arrival or have a previous history of aortic disease
  9. whose legal representative has requested termination of resuscitation efforts before study enrollment
  10. declared dead at scene before randomization
  11. Patients who meet the criteria for extracorporeal cardiopulmonary resuscitation (ECPR), and therefore the decision is made to perform ECPR, will not be enrolled. The ECPR criteria applies when all of the following criteria are met: pre-cardiac arrest CPC of 1-2, witnessed cardiac arrest with bystander CPR, ages between 20-70, initial shockable rhythm, ECMO pump-on available within 60 minutes of onset of cardiac arrest, and patients without end-stage diseases such as cancer, liver cirrhosis, or end-stage renal failure.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
234 participants (estimated)

Study arms

  • No intervention
    Control

    Patients allocated to this arm receives conventional resuscitative measures according to the 2020 AHA CPR Guidelines.

  • Experimental
    REBOA

    After enrollment and randomization, patients allocated to this arm receives REBOA in addition to conventional ACLS according to the 2020 AHA CPR guidelines. The common femoral artery is accessed with ultrasound guidance. A sheath catheter is inserted, followed by a REBOA catheter. The REBOA is ballooned with 20cc of normal saline or until resistance is felt.

    Device: REBOA

Interventions

  • DeviceREBOA

    Resuscitative endovascular balloon occlusion of the aorta (REBOA)is a device composed of a catheter attached to an inflatable balloon. It is inserted through the common femoral artery and guided to the thoracic aorta.

06

What researchers measure

Primary outcomes

  1. Number of Participants Who Achieved ROSC (return of spontaneous circulation)

    Number of patients who achieves ROSC regardless of sustained time

    Time frame: 24 hours

Secondary outcomes

  1. Number of Participants Who Achieved Sustained ROSC

    Number of participants who achieves sustained ROSC (ROSC maintained more than 20 minutes)

    Time frame: 24 hours

  2. Survival to Admission

    Whether patients who achieve sustained ROSC survives until admission

    Time frame: 48 hours

  3. Survival to Discharge

    Whether patients survive until hospital discharge.

    Time frame: 30 days

  4. Neurological Outcome

    The cerebral performance category (CPC) and modified Rankin Score (mRS) of each patient at 28 days, 3 months, and 6 months after achieving ROSC. CPC is measured on a scale of 1 to 5, with 1 being the best neurological performance, and 5 indicating brain death. MRS is measured on a scale of 0 to 6, with 0 indicating no neurological deficit, and 6 indicating death.

    Time frame: 1 month, 3 months, 6 months since ROSC

  5. Changes in Arterial Blood Pressure

    Arterial blood pressure measured before and after REBOA inflation in the experimental group. Both systolic and diastolic pressures will be used.

    Time frame: ABP 2 minutes and 1 minute before REBOA insertion, ABP 1 minute / 2 minutes / 4 minutes / 10 minutes after REBOA insertion.

07

Study locations

1 of 1 sites recruiting
  • Seoul National Univeristy Bundang Hospital
    Seongnam-si, Gyeonggi-do 13620, Korea, Republic of
    Recruiting
08

References and documents

Publications

  • Jang DH, Lee DK, Jo YH, Park SM, Oh YT, Im CW. Resuscitative endovascular occlusion of the aorta (REBOA) as a mechanical method for increasing the coronary perfusion pressure in non-traumatic out-of-hospital cardiac arrest patients. Resuscitation. 2022 Oct;179:277-284. doi: 10.1016/j.resuscitation.2022.07.020. Epub 2022 Jul 21. PubMed 35870557 ↗
  • Brede JR, Lafrenz T, Klepstad P, Skjaerseth EA, Nordseth T, Sovik E, Kruger AJ. Feasibility of Pre-Hospital Resuscitative Endovascular Balloon Occlusion of the Aorta in Non-Traumatic Out-of-Hospital Cardiac Arrest. J Am Heart Assoc. 2019 Nov 19;8(22):e014394. doi: 10.1161/JAHA.119.014394. Epub 2019 Nov 11. PubMed 31707942 ↗
  • Mazzoli CA, Chiarini V, Coniglio C, Lupi C, Tartaglione M, Gamberini L, Semeraro F, Gordini G. Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) in Non-Traumatic Cardiac Arrest: A Narrative Review of Known and Potential Physiological Effects. J Clin Med. 2022 Jan 29;11(3):742. doi: 10.3390/jcm11030742. PubMed 35160193 ↗
  • Daley J, Morrison JJ, Sather J, Hile L. The role of resuscitative endovascular balloon occlusion of the aorta (REBOA) as an adjunct to ACLS in non-traumatic cardiac arrest. Am J Emerg Med. 2017 May;35(5):731-736. doi: 10.1016/j.ajem.2017.01.010. Epub 2017 Jan 12. PubMed 28117180 ↗
  • Nowadly CD, Johnson MA, Hoareau GL, Manning JE, Daley JI. The use of resuscitative endovascular balloon occlusion of the aorta (REBOA) for non-traumatic cardiac arrest: A review. J Am Coll Emerg Physicians Open. 2020 Aug 30;1(5):737-743. doi: 10.1002/emp2.12241. eCollection 2020 Oct. PubMed 33145513 ↗
  • Hutin A, Levy Y, Lidouren F, Kohlhauer M, Carli P, Ghaleh B, Lamhaut L, Tissier R. Resuscitative endovascular balloon occlusion of the aorta vs epinephrine in the treatment of non-traumatic cardiac arrest in swine. Ann Intensive Care. 2021 May 17;11(1):81. doi: 10.1186/s13613-021-00871-z. PubMed 34002305 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2023 (actual). Primary completion is estimated for Oct 2025, 23 months after the start.

Of 205 non-industry interventional studies with no phase under Heart Arrest, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 47. This study's planned 23 months is below that.

Counting every sponsor, half of 219 studies reached it within 28 months; a quarter within 10 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 2, 2023
First posted
Sep 11, 2023
StartActual
Oct 17, 2023
Primary completionEst.
Oct 1, 2025
CompletionEst.
Oct 1, 2026
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06031623
Responsible party
Dong Keon Lee (Associate professor, Seoul National University Hospital) — Principal investigator
First posted
Sep 11, 2023
Start date
Oct 17, 2023
Primary completion
Oct 1, 2025 (estimated)
Completion
Oct 1, 2026 (estimated)
Last update
Jan 28, 2025

Study contacts

Hee Eun Kim
Contact
hekim9111@gmail.com
82-31-787-7579
Dong Hyun Jang
Contact
jang0621@gmail.com
82-31-787-7819

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion